Adalimumab and infliximab survival in patients with hidradenitis suppurativa: a daily practice cohort study

BACKGROUND: Biologics are often required for the treatment of hidradenitis suppurativa (HS). However, data on the drug survival of biologics in daily practice are currently lacking. OBJECTIVES: To assess the drug survival of antitumour necrosis factor biologics in a daily practice cohort of patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Prens, L.M., Bouwman, K., Aarts, P., Arends, S., van Straalen, K.R., Dudink, K., Horváth, B., Prens, E.P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8360014/
https://www.ncbi.nlm.nih.gov/pubmed/33544917
http://dx.doi.org/10.1111/bjd.19863

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8360014/
https://www.ncbi.nlm.nih.gov/pubmed/33544917
http://dx.doi.org/10.1111/bjd.19863

Ejemplares similares